Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
作者信息
Martin Thomas, Dimopoulos Meletios-Athanasios, Mikhael Joseph, Yong Kwee, Capra Marcelo, Facon Thierry, Hajek Roman, Špička Ivan, Baker Ross, Kim Kihyun, Martinez Gracia, Min Chang-Ki, Pour Ludek, Leleu Xavier, Oriol Albert, Koh Youngil, Suzuki Kenshi, Casca France, Macé Sandrine, Risse Marie-Laure, Moreau Philippe
机构信息
Department of Hematology, University of California at San Francisco, San Francisco, CA, USA.
The National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038/s41408-023-00923-6.
Abstract
摘要
相似文献
1
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.更正：复发多发性骨髓瘤患者使用isatuximab、卡非佐米和地塞米松：IKEMA（一项随机3期研究）的更新结果。
Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038/s41408-023-00923-6.
2
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤（IKEMA）：一项多中心、开放标签、随机3期试验
Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.
3
Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.依沙佐米、卡非佐米和地塞米松（Isa-Kd）治疗多发性骨髓瘤复发。
Future Oncol. 2021 Dec;17(35):4849-4860. doi: 10.2217/fon-2021-0778. Epub 2021 Sep 23.
4
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.isatuximab联合卡非佐米和地塞米松治疗东亚复发多发性骨髓瘤患者：IKEMA研究组更新分析
Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3.
5
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.依沙佐米联合卡非佐米/地塞米松与卡非佐米/地塞米松治疗复发/难治性多发性骨髓瘤患者的随机、开放、III 期研究设计（IKEMA 研究）。
Future Oncol. 2020 Jan;16(2):4347-4358. doi: 10.2217/fon-2019-0431. Epub 2019 Dec 13.
6
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.依鲁替尼联合卡非佐米和地塞米松与卡非佐米和地塞米松治疗复发多发性骨髓瘤患者：IKEMA 亚组分析（按既往移植情况）。
Transplant Cell Ther. 2023 Feb;29(2):134.e1-134.e7. doi: 10.1016/j.jtct.2022.11.005. Epub 2022 Nov 11.
7
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.依沙佐米联合卡非佐米和地塞米松与卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤老年患者的疗效：IKEMA 亚组分析。
Hematol Oncol. 2022 Dec;40(5):1020-1029. doi: 10.1002/hon.3038. Epub 2022 Jun 8.
8
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.依鲁替尼联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤的疗效观察：IKEMA 亚组分析
Int J Hematol. 2022 Oct;116(4):553-562. doi: 10.1007/s12185-022-03378-w. Epub 2022 May 17.
9
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.isatuximab联合卡非佐米和地塞米松治疗日本复发多发性骨髓瘤患者：随机、开放标签、3期IKEMA研究的亚组分析
Jpn J Clin Oncol. 2022 Dec 5;52(12):1446-1449. doi: 10.1093/jjco/hyac137.
10
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.高危细胞遗传学的复发多发性骨髓瘤患者中伊沙妥昔单抗联合卡非佐米和地塞米松：IKEMA 亚组分析。
Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18.
引用本文的文献
1
Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.B细胞血液系统恶性肿瘤的潜在替代终点：一项系统评价和荟萃分析。
Sci Rep. 2025 Jun 2;15(1):19300. doi: 10.1038/s41598-025-05053-6.
2
Signaling pathways in liver cancer: pathogenesis and targeted therapy.肝癌信号通路：发病机制与靶向治疗。
Mol Biomed. 2024 May 31;5(1):20. doi: 10.1186/s43556-024-00184-0.
Zotero 插件